StockData
Kyverna Therapeutics, Inc. logo

Kyverna Therapeutics, Inc. (KYTX) stock

KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$4.48−0.22 (-4.68%)

Close on Nov 18, 2026Market cap $277.06MP/E –Yield –

Kyverna Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Kyverna Therapeutics's price to book ratio was 1.9× on Nov 11, 2026, against 2.2× a year earlier. Over the last 3 years it ranged from 0.3× to 3.2×, with a median of 1.4×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.9×−0.8
2025Dec 31, 20252.7×+2.2
2024Dec 31, 20240.5×–

More Kyverna Therapeutics figures

See a number that looks wrong?